MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
Abstract
The development of Alzheimer's disease (AD) biomarkers remains an unmet challenge, and new approaches that can improve current AD biomarker strategies are needed. Recent reports suggested that microRNA (miRNA) profiling of biological fluids has emerged as a diagnostic tool for several pathologic conditions. In this study, we measured six candidate miRNAs (miR-9, miR-29a, miR-29b, miR-34a, miR-125b, and miR-146a) in plasma and cerebrospinal fluid (CSF) of AD and normal subjects by using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to evaluate their potential usability as AD biomarkers. The qRT-PCR results showed that plasma miR-34a and miR-146a levels, and CSF miR-34a, miR-125b, and miR-146a levels in AD patients were significantly lower than in control subjects. On the other hand, CSF miR-29a and miR-29b levels were significantly higher than in control subjects. Our results provide a possibility that miRNAs detected in plasma and CSF can serve as biomarkers for AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miR-34 dysregulation is related to schizophrenia, Alzheimer's disease, and MDD.
“miR-34 dysregulation is related to different psychiatric disorders, including schizophrenia236, Alzheimer’s disease,237 and MDD.238”
From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [237]
There has been a lack of consistent findings among studies of microRNAs in cerebrospinal fluid.
“However, there has been a lack of consistent findings among CSF microRNAs studies.”
From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [13]
The level of miR-125b was reported to be significantly increased, decreased, or not altered in the CSF of AD patients.
“The level of miR-125b was reported to be significantly increased11, decreased13,14, or not altered16 in the CSF of AD patients.”
From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [13]
The citation lists haven’t been fetched yet
References 50 · Cited by 256
- Authors
- Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Nakagawa, Kiyotaka
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2014-01-24
- Volume
- 39
- Issue
- 2
- Pages
- 253-259
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1920972969
- Cited by
- 256
- References
- 50
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 21 · 2023: 19 · 2022: 24 · 2021: 26 · 2020: 21 · 2019: 24 · 2018: 20 · 2017: 21 · 2016: 20 · 2015: 28 · 2014: 13 · 2012: 1
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (24390179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, microRNA
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Peptide Fragments, Psychiatric Status Rating Scales, Biomarkers, Amyloid beta-Peptides, tau Proteins, Reverse Transcriptase Polymerase Chain Reaction, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
